Lyn Jones completed PhD studies in synthetic organic chemistry at the University of Nottingham, before starting his post-doctorate research at The Scripps Research Institute, California in the area of chemical biology. In 2001, he joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader. In 2011, he transferred to Cambridge, MA to become Head of Rare Disease Chemistry and to lead the Chemical Biology Group, before joining Jnana Therapeutics in 2017 as Vice President of Chemistry and Chemical Biology. He is currently Chief Scientist at the Center for Protein Degradation at the Dana-Farber Cancer Institute. In 2009, he won the inaugural Royal Society of Chemistry Young Industrialist of the Year Award for his contributions to HIV and COPD research and clinical candidate delivery. He is an author or inventor on over 100 publications and patents, a fellow of the Royal Society of Chemistry (FRSC), the Royal Society of Biology (FRSB) and the Linnean Society.